Towards More Selective Senolytic Drugs to Clear Senescent Cells from Aged Tissues
Cells enter a senescent state constantly throughout life, largely as a result of reaching the Hayflick limit on cellular replication, but also due to damage and stress. Senescent cells cease to replicate and begin to secrete pro-inflammatory, pro-growth signals. This attracts the immune system to sites of potential concern, and in the case of physical injuries to tissue the signaling of senescent cells helps to coordinate repair. Senescent cells are normally cleared from tissues fairly quickly, being destroyed either by immune cells, or via programmed cell death mechanisms. With age, however, the pace of clearance slows an...
Source: Fight Aging! - October 4, 2023 Category: Research Authors: Reason Tags: Medicine, Biotech, Research Source Type: blogs
Airway hemorrhage in Eisenmenger syndrome
In Eisenmenger syndrome airway hemorrhages have to be thought of specially when moving from lower to a higher altitude as during air travel or while ascending a mountain. Hemoptysis has been reported as a cause of death in Eisenmenger syndrome in 11-29% [1].
Defects in hemostatic mechanism due to abnormal platelet function, thrombocytopenia, deficiencies of clotting factor as well as depletion of von Willebrand factor may also contribute to airway hemorrhages in Eisenmenger syndrome [2].
References
Jensen AS, Iversen K, Vejlstrup NG, Sondergaard L. Pulmonary artery thrombosis and hemoptysis in Eisenmenger syndrome. ...
Source: Cardiophile MD - November 20, 2022 Category: Cardiology Authors: Johnson Francis Tags: General Cardiology Source Type: blogs
What Is Blood Anyway?
A few years ago I had a great opportunity to write an article series for EMS Magazine called Blood On Tap. It was all about the pioneering work being done by different pharmaceutical groups to create artificial substitutes for blood.
The technical name for the pharmaceutical products that mimic the properties of blood is “oxygen therapeutics.” Here’s the inside scoop, directly from the drug company big wigs, on why we don’t call them something cool like artificial blood.
The thing is, the drug company’s know full well that these fancy solutions are nowhere near advanced enough to mimic the many complex...
Source: The EMT Spot - November 10, 2022 Category: Emergency Medicine Authors: Steve Whitehead Tags: EMT Source Type: blogs
PicnicHealth Raises a $60m Series C to Expand Patient-centered Real-world Data
PicnicHealth, a patient-centered health technology company, today announced the closing of a $60 million Series C financing led by new investor B Capital Group. Existing investors Felicis Ventures and Amplify Partners also joined the round, bringing the total PicnicHealth has raised to more than $100 million. The company also announced plans to build 30 new patient-centered real-world data cohorts, and the addition of Adam Seabrook, Partner at B Capital Group, to the PicnicHealth board of directors.
PicnicHealth takes a patient-centered approach to building deep real-world datasets for life sciences researchers. This compl...
Source: EMR and HIPAA - July 1, 2022 Category: Information Technology Authors: Healthcare IT News Tags: Analytics/Big Data Health IT Company Healthcare IT Adam Seabrook Amplify Partner B Capital Group Felicis Ventures Health IT Funding Health IT Fundings Health IT Investment Noga Leviner PicnicHealth Real-World Data Robert Mittendo Source Type: blogs
Fight Aging! Newsletter, April 18th 2022
In conclusion, our results suggest that SAH extends lifespan by inducing MetR or mimicking its downstream effects. Since the lifespan-extending effects of SAH are conserved in yeast and nematodes, and MetR extends the lifespan of many species, exposure to SAH is expected to have multiple benefits across evolutionary boundaries. Our findings offer the enticing possibility that in humans the benefits of a MetR diet can be achieved by promoting Met reduction with SAH. The use of endogenous metabolites, such as SAH, is considered safer than drugs and other substances, suggesting that it may be one of the most feasible ways to ...
Source: Fight Aging! - April 17, 2022 Category: Research Authors: Reason Tags: Newsletters Source Type: blogs
Systematic Screening of Cell Death Pathways in Search of New Senolytics
Senolytic drugs capable of clearing senescent cells from the bodies of older people will be a very important part of the medicine of tomorrow. A burden of senescent cells contributes significantly to aging, and removing them produces quite rapid and profound rejuvenation in animal models. If taking the small molecule drug approach, a diversity of senolytics will likely be needed in order to clear most senescent cells from most tissues, due to differences in drug biodistribution and biochemistry of senescence between tissue types. The search for new senolytic drug targets and drug compounds has been underway in earnest for ...
Source: Fight Aging! - April 11, 2022 Category: Research Authors: Reason Tags: Daily News Source Type: blogs
D-Cube syndrome : DES-Dengue-DAPT
Background
A 52-year-old diabetic woman who had undergone recent PCI with a DES developed a febrile illness which was diagnosed as Dengue fever. She has been taking DAPT (Dual antiplatelet) meticulously to maintain her stent. Now, her platelet count has dropped from 1.5 and subsequently to 1 lakh. She is asking now, whether to stop DAPT or not? What is the risk of stent occlusion if she stops?
The D³ cube syndrome
Infectious diseases rarely bother a cardiologist (maybe a few IE, myocarditis, etc). Now, a unique situation is emerging.
*Dengue affects 50-100 million people worldwide every year and one billion are ...
Source: Dr.S.Venkatesan MD - September 9, 2021 Category: Cardiology Authors: dr s venkatesan Tags: anti platelet drug antiplatelet drugs in dengue clopidogrel prasugrel ticagrelol in dengue fever dapt in dengue fever therapeutic issues in dengue and cad warfarin heparin in dengue Source Type: blogs
I Am Sure The Technology Investments In Many States Are Paying Off In This Search!
This appeared last week: NSW hospitals hunt for rare blood clots linked to AstraZeneca vaccine By Kate Aubusson April 8, 2021 — 5.00am NSW emergency departments are scouring medical records for blood clot cases linked to the AstraZeneca COVID-19 vaccine as international medicines regulators inch closer to declaring the vaccine may cause the extremely rare condition. The state’s vaccinators are warning anyone receiving the AstraZeneca shot to be on alert for blood clot symptoms as a precaution following the case of a 44-year-old man hospitalised with a severe and extremely rare clotting disorder in Melbourne on Friday. ...
Source: Australian Health Information Technology - April 16, 2021 Category: Information Technology Authors: Dr David G More MB PhD Source Type: blogs
COVID-vaccine induced thrombosis as explained by a hematologist
VIPIT is the medical term given to the phenomenon of developing clots in various parts of the body after certain (not all) COVID-19 vaccines. VIPIT stands for vaccine-induced prothrombotic immune thrombocytopenia, a complicated term explained simply as clotting of the thrombocytes or platelet cells in the blood vessels after receiving the COVID vaccine. Clearly, understanding […]Find jobs at Careers by KevinMD.com. Search thousands of physician, PA, NP, and CRNA jobs now. Learn more. (Source: Kevin, M.D. - Medical Weblog)
Source: Kevin, M.D. - Medical Weblog - April 11, 2021 Category: General Medicine Authors: < span itemprop="author" > < a href="https://www.kevinmd.com/blog/post-author/akshat-jain" rel="tag" > Akshat Jain, MD < /a > < /span > Tags: Conditions COVID-19 coronavirus Infectious Disease Source Type: blogs
A woman in her 40s with acute chest pain
Case written by Neha Ray MD, Brandon Fetterolf MD, and Pendell Meyers MDA woman in her 40s with a history of rheumatoid arthritis, anemia, and thrombocytopenia presented to the ED with acute onset chest pain starting around 5am on the morning of presentation. It woke her from sleep. The chest pain was midsternal, severe, sharp, and constant. On the previous night she had had a mild version of the same pain that she thought was heartburn (esophageal reflux). She reported some radiation to the left arm. She also reports 3 episodes of non-bloody vomiting over the course of the morning. She had a recent admission fo...
Source: Dr. Smith's ECG Blog - November 29, 2020 Category: Cardiology Authors: Pendell Source Type: blogs
Adverse effects of hydroxychloroquine
In case you were ever stupid enough to follow Trump’s lead you would have already injected ultraviolets in your eyeballs by now to save you from Covid and maybe bathed in Domestos or sulfuric acid or both! Anyway, his latest bullshine claim is that he’s been taking the antimalarial drug hydroxychloroquine to keep Covid at bay.
Well, for starters there is no evidence that this drug acts as a prophylactic against infection with SARS CoV-2 or indeed any pathogen other than the causative agent of otherwise drug-resistant malaria. It’s primary use is in treating lupus. There was some testing done weeks ago to...
Source: David Bradley Sciencebase - Songs, Snaps, Science - May 19, 2020 Category: Science Authors: David Bradley Tags: Health and Medicine Source Type: blogs
Clinical characteristics and predictors of outcomes of hospitalised patients with COVID-19 in a London NHS trust: a retrospective cohort study
This report is one of the first studies to describe the characteristics and predictors of outcome for hospitalised Covid-19 patients in the UK. It finds that older age, male sex and admission hypoxia, thrombocytopenia, renal failure, hypoalbuminaemia and raised bilirubin are associated with increased odds of death. Ethnic minority groups were over-represented in the cohort and, compared to whites, people of black ethnicity may be at increased odds of mortality.ReportMore detail (Source: Health Management Specialist Library)
Source: Health Management Specialist Library - May 4, 2020 Category: UK Health Authors: The King ' s Fund Library Tags: Equality and diversity Local authorities, public health and health inequalities Source Type: blogs
Fight Aging! Newsletter, May 4th 2020
The objective is to start treating chronic diseases from the root and not the symptoms of the disease. As we are starting to enroll patients in "senolytics-clinical trials," it will be imperative to assess if senolysis efficiently targets the primary cause of disease or if it works best in combination with other drugs. Additional basic science research is required to address the fundamental role of senescent cells, especially in the established contexts of disease.
Notes on Self-Experimentation with Sex Steroid Ablation for Regrowth of the Thymus
https://www.fightaging.org/archives/2020/04/notes-on-self-experi...
Source: Fight Aging! - May 3, 2020 Category: Research Authors: Reason Tags: Newsletters Source Type: blogs
Turning Navitoclax into a PROTAC Senolytic with a Better Safety Profile
It is interesting to compare today's open access paper on converting the senolytic drug navitoclax into a PROTAC with recent efforts to improve navitoclax by conjugation with galactose. In both cases the objective is to reduce side-effects, but the strategies are quite different. Navitoclax is arguably the worst of the viable first generation senolytic drugs capable of selectively destroying senescent cells in old tissues. Senescent cells accumulate with age and cause great harm via their inflammatory signaling. Removing them has been shown to extend healthy life, reverse aspects of aging, and turn back a wide range of age...
Source: Fight Aging! - May 1, 2020 Category: Research Authors: Reason Tags: Medicine, Biotech, Research Source Type: blogs
Quinidine for Brugada syndrome
Brugada syndrome is an inherited cardiac channelopathy with potential for life threatening ventricular arrhythmias and sudden cardiac death [1]. Coved ST segment elevation of 2 mm or more with negative T wave in right precordial leads V1 and V2, either spontaneously or after challenge with sodium channel blocker drug is the characteristic ECG finding. Though implantation of an ICD (implantable cardioverter-defibrillator is the main treatment, quinidine for Brugada syndrome is an option worth it in certain situations [2].
Quinidine is a Class I antiarrhythmic agent which can block Ito and IKr currents. It has been shown to...
Source: Cardiophile MD - April 19, 2020 Category: Cardiology Authors: Prof. Dr. Johnson Francis Tags: Cardiology Source Type: blogs
